A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

May 16, 2026

Study Completion Date

August 31, 2026

Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
DRUG

LUNA18

LUNA18 Capsule

DRUG

Cetuximab

Cetuximab as a IV infusion

Trial Locations (20)

10029

Icahn School of Medicine at Mount Sinai, New York

19106

Abramson Cancer Center at Pennsylvania Hospital, Philadelphia

22031

NEXT Virginia, Fairfax

48201

Barbara Ann Karmanos Cancer Institute, Detroit

49546

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids

53792

University of Wisconsin - Carbone Cancer Center, Madison

77030

MD Anderson Cancer Center, Houston

78758

NEXT Oncology, Austin

89502

Renown Regional Medical Center, Reno

95616

University of California - Davis, Davis

02215

Beth Israel Deaconess, Boston

Dana-Farber Cancer Institute, Boston

02903

Rhode Island Hospital-Comprehensive Cancer Center, Providence

464-8681

Aichi Cancer Center, Nagoya

277-8577

National Cancer Center Hospital East, Kashiwa

411-0934

Shizuoka Cancer Center, Nakatogari

104-0045

National Cancer Center Hospital, Chuo-Ku

135-8550

The Cancer Institute Hospital of JFCR, Koto-ku

811-1395

National Hospital Organization Kyushu Cancer Center, Fukuoka

541-8567

Osaka International Cancer Institute, Osaka

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY